HIGHLIGHTS
- who: Envisage - 004 from the Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, PRChina have published the article: The cell senescence regulator p16 is a promising cancer prognostic and immune check-point inhibitor (ICI) therapy biomarker, in the Journal: (JOURNAL)
- what: This study attempted to investigate whether CDKN2A can be used as a robust tumor marker and play a role in pan-cancer immunotherapy, thereby AGING providing some clues for tumor immunotherapy strategy. That`s the primary motivation to search the immunotherapy response predictive efficiency of CDKN2A, as a biomarker under . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.